跳转至内容
Merck
CN
  • Posttreatment changes in cytokines induced by Schistosoma mansoni egg and worm antigens: dissociation of immunity- and morbidity-associated type 2 responses.

Posttreatment changes in cytokines induced by Schistosoma mansoni egg and worm antigens: dissociation of immunity- and morbidity-associated type 2 responses.

The Journal of infectious diseases (2013-12-21)
Shona Wilson, Frances M Jones, Lee-Carol Kenty, Joseph K Mwatha, Gachuhi Kimani, H Curtis Kariuki, David W Dunne
摘要

Human type 2 cytokine responsiveness to schistosome antigens increases after treatment; due either to removal of the immunosuppressive effects of active infection or immunological boosting by antigens released from dying parasites. We determined the responsiveness to Schistosoma mansoni over a 2-year period, when reinfection was restricted by interrupting transmission. The proinflammatory and type 2 responses of Kenyan schoolchildren were measured before, and 1 year and 2 years posttreatment in whole blood cultures stimulated with soluble egg antigen (SEA) or soluble worm antigen (SWA). The site of S. mansoni transmission was molluscicided throughout. Pretreatment proinflammatory responses to SEA were high but reduced 1 and 2 years posttreatment, whereas type 2 responses were low pretreatment and increased 1 and 2 years posttreatment. Type 2 responses to SWA were high pretreatment and increased at 1 year, with no further increases at 2 years posttreatment. Children infected at follow-up had lower SEA, but not SWA, posttreatment type 2 responsiveness. Increases at 1 year in type 2 SWA, but not SEA, responsiveness correlated with pretreatment egg counts. Removal of immunosuppressive effects of active infection increases SEA type 2 responsiveness; long-term SWA type 2 responsiveness is due to treatment-induced immunological boosting. Dissociation of type 2 responses potentially protects against severe egg-associated immunopathology during infection, while allowing worm-antigen derived immunity to develop.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
磷酸三丁酯, ≥99%
Sigma-Aldrich
磷酸三丁酯, 97%
Supelco
吡喹酮, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
磷酸三丁酯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
磷酸三丁酯, puriss., ≥99.0% (GC)
Supelco
吡喹酮, VETRANAL®, analytical standard
磷酸三正丁酯, European Pharmacopoeia (EP) Reference Standard
Supelco
磷酸三丁酯, for extraction analysis, ≥99.0% (GC)
吡喹酮, European Pharmacopoeia (EP) Reference Standard
吡喹酮, European Pharmacopoeia (EP) Reference Standard